First, the misregulation of Ddx5 and/or Ddx17 expression level and/or activity owing to posttranslational modifications that was reported in many cases of breast and prostate cancer (10,23,43–45), may have a broad impact on the estrogen- and androgen-signaling pathways that play a major role in the etiology and progression of those cancers. This evidence concerns the gene DDX5 and prostate cancer.